Congress expands national security screening to biotech deals—with minimal guardrails.

What it does

This bill expands the Defense Production Act to treat biotechnology (pharmaceuticals, biologics, drug discovery, and clinical research) as a national security technology subject to outbound investment screening. It requires the Treasury Secretary, in consultation with Defense, Health and Human Services, and Intelligence officials, to define which biotech transactions with foreign entities—especially China—must be reported or prohibited. The bill aims to prevent U.S. capital and intellectual property from flowing to Chinese biotech firms through licensing, joint ventures, and equity investments.

Why we flagged it

The bill's core mechanism is to extend Defense Production Act outbound investment screening to biotechnology, treating it as a dual-use national security technology. This is a regulatory expansion, not a subsidy or carve-out, but it delegates substantial definitional authority to the executive branch with limited statutory guardrails.

What the text implies

• The bill grants Treasury, Defense, HHS, and Intelligence broad discretion to define 'prohibited' and 'notifiable' biotech transactions with minimal statutory limits, creating regulatory uncertainty that may chill legitimate U.S.-foreign biotech partnerships and licensing deals.
• By targeting 'covered foreign persons' and emphasizing China specifically in findings but not in operative text, the rule-making process may apply screening asymmetrically, potentially affecting allies' biotech firms differently than Chinese competitors.
• Licensing transactions, drug discovery platforms, and clinical research capabilities are explicitly flagged for 'priority' screening, which may slow or block U.S. biotech companies from out-licensing IP to foreign partners—reducing revenue and incentives for domestic innovation.
• The bill does not define 'strategic dependency risk' or establish a cost-benefit test for blocking transactions, leaving the executive branch free to err on the side of restriction without weighing harm to patients, drug development timelines, or U.S. biotech competitiveness.
• Requiring consultation with Intelligence and Defense on commercial biotech licensing may blur the line between national security and industrial policy, creating precedent for screening other high-tech sectors on vague 'dependency' grounds.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill may protect U.S. pharmaceutical supply chains and reduce strategic dependency on China, a legitimate public-interest goal. However, it creates broad regulatory authority over private biotech investment and licensing with minimal transparency guardrails, potentially raising costs for U.S. biotech companies, slowing drug development partnerships, and reducing access to international collaboration—effects that could ultimately harm patients through delayed or more expensive treatments.

Who stands to gain

• U.S. biotech and pharmaceutical companies (reduced foreign competition for licensing deals)
• U.S. government contractors in biodefense and pharmaceutical manufacturing
• Domestic clinical research organizations (reduced foreign outsourcing)

Named in the bill

Defense Production Act of 1950, Treasury Secretary, Secretary of Defense, Secretary of Health and Human Services, Director of National Intelligence, People's Republic of China, BIOSECURE Act, National Defense Authorization Act for Fiscal Year 2026, Federal Food, Drug, and Cosmetic Act, Public Health Service Act, House Committee on Financial Services, House Committee on Armed Services — and 2 more

Where it stands

1 cosponsor: 1 Democrats.

• Jun 2, 2026 — Introduced · Congress.gov: “Introduced in House”
• Jun 2, 2026 — Referred to House Committee on Financial Services · Congress.gov: “Referred to the House Committee on Financial Services”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

13 lobbying clients named this bill on 13 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $18,610,000 in lobbying spend. A filing names 19 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 94% of bills with at least one filing.

John Moolenaar, the sponsor, reported $595,100 in PAC receipts in the 2026 cycle. $1,000 of that came from 1 PAC tied to these lobbying clients.

• Pharmaceutical Research and Manufacturers of America — $7,360,000 on 1 filing
• Amgen Inc — $2,440,000 on 1 filing
• Biotechnology Innovation Organization — $2,360,000 on 1 filing
• Pfizer Inc. — $1,880,000 on 1 filing
• Novartis — $1,410,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.